NCT00955591 is a NA clinical trial of Papanicolaou test in Anal Cancer, sponsored by Jonsson Comprehensive Cancer Center.

Who is sponsoring NCT00955591?

NCT00955591 is sponsored by Jonsson Comprehensive Cancer Center.

What drugs are being tested in NCT00955591?

Interventions in NCT00955591: Papanicolaou test.

What condition does NCT00955591 study?

NCT00955591 studies Anal Cancer, Nonneoplastic Condition, Precancerous Condition.

Is NCT00955591 still recruiting?

NCT00955591 is currently completed. Last updated 3 August 2020.

Last reviewed 2020-08-03 · How we verify

NCT00955591

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men

Completed NA Last updated 3 August 2020

What this trial tests

NA trial testing Papanicolaou test in Anal Cancer in 48 participants. Completed in 14 October 2016.

Timeline

12 March 2009

Primary endpoint
12 December 2011

14 October 2016

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	48
Start date	12 March 2009
Primary completion	12 December 2011
Estimated completion	14 October 2016
Sites	1 location across United States

Drugs / interventions tested

Papanicolaou test

Conditions studied

Anal Cancer — all drugs for Anal Cancer →
Nonneoplastic Condition — all drugs for Nonneoplastic Condition →
Precancerous Condition — all drugs for Precancerous Condition →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

18 and older, male only, with Anal Cancer or Nonneoplastic Condition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Doctors use a swab to collect cell samples when testing for anal cancer and human papillomavirus. It is not yet known which type of swab is more effective in collecting cell samples for anal Pap tests and human papillomavirus tests in men who have sex with men. PURPOSE: This clinical trial is comparing two types of swabs in collecting cell samples for anal Pap tests and human papillomavirus tests in men who have sex with men.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of 2 anal cytology protocols to predict high-grade anal intraepithelial neoplasia.
Wiley DJ, Hsu H, Bolan R, Voskanian A, et al · · 2013 · cited 12× · PMID 23595039 · DOI 10.1097/lgt.0b013e318281d36e

Verify or expand the search:

Other recruiting trials for Anal Cancer

Currently open trials in the same condition.

NCT07192055 — Self-sampling to Optimize Anal Lesion Outcomes · NA · recruiting
NCT07296237 — Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer · recruiting
NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
NCT06670495 — HPV Genotype Attribution and Disease Burden of Anal Cancer in China · recruiting

Other Jonsson Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00955591 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 3 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00955591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing